Were Maze Therapeutics (MAZE) CEO Jason Coloma’s share sales made under a Rule 10b5-1 plan?

Yes. A footnote explains the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026. Such plans pre-schedule trades, indicating these sales were part of a predetermined program rather than opportunistic timing.

Maze Therapeutics (MAZE) CEO sells 27,858 shares under 10b5-1 trading plan

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Maze Therapeutics, Inc. director and Chief Executive Officer Jason V. Coloma reported indirect open-market sales totaling 27,858 shares of common stock. The Coloma Family Trust and The Coloma 2021 Irrevocable Trust, for which Coloma and his spouse serve as co-trustees, executed these trades at weighted average prices near $26 per share. The filing notes the transactions were made pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026, indicating they were pre-arranged rather than discretionary market-timed sales.

Insights

CEO’s 27,858-share 10b5-1 sales look routine relative to remaining holdings.

Director and CEO Jason V. Coloma, through the Coloma Family Trust and a 2021 irrevocable trust, executed open-market sales of 27,858 Maze Therapeutics shares at weighted average prices around $26. All transactions are coded as non-derivative sales (S), with no option exercises involved.

The trusts continue to hold substantial positions after the trades, as shown by six-figure post-transaction share balances in the filing. A footnote states the sales were carried out under a Rule 10b5-1 trading plan adopted on February 6, 2026, suggesting a pre-scheduled liquidity program rather than ad hoc selling based on short-term news.

Given the modest scale relative to the remaining indirect holdings and the pre-planned nature, these sales typically carry limited informational value about management’s view of the company. Subsequent company filings may provide additional context on any broader equity ownership or compensation trends.

Insider Trade Summary 10b5-1

Net Seller: 27,858 shares ($725,495)

Net Sell 3 txns

Insider Coloma Jason V

Role Chief Executive Officer

Sold 27,858 shs ($725K)

Type	Security	Shares	Price	Value
Sale	Common Stock	23,865	$26.0496	$622K
Sale	Common Stock	1,953	$26.0015	$51K
Sale	Common Stock	2,040	$26.00	$53K

Holdings After Transaction: Common Stock — 319,079 shares (Indirect, Coloma Family Trust)

Footnotes (1)

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.025 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 5 of this Form 4. These securities are directly held by the Coloma Family Trust (the "Family Trust"), for which the reporting person and his spouse serve as co-trustees. These securities are directly held by The Coloma 2021 Irrevocable Trust (the "Irrevocable Trust"), for which the reporting person and his spouse serve as co-trustees. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.185 per share, inclusive.

Key Figures

Shares sold: 27,858 shares June 23 sale size: 23,865 shares June 23 price: $26.0496 per share +5 more

8 metrics

Shares sold 27,858 shares Total net shares sold across reported transactions

June 23 sale size 23,865 shares Common stock sold indirectly by Coloma Family Trust on June 23, 2026

June 23 price $26.0496 per share Weighted average sale price for June 23, 2026 transaction

June 22 Family Trust sale 1,953 shares Common stock sold indirectly by Coloma Family Trust on June 22, 2026

June 22 Irrevocable Trust sale 2,040 shares Common stock sold indirectly by 2021 Irrevocable Trust on June 22, 2026

Price range (Family Trust) $26.00–$26.185 per share Range of prices for certain sales noted in footnote F5

Price range (Irrevocable Trust) $26.00–$26.025 per share Range of prices for certain sales noted in footnote F2

10b5-1 plan adoption date February 6, 2026 Date CEO adopted Rule 10b5-1 trading plan for these sales

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale, Irrevocable Trust, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The reported price in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Irrevocable Trust financial

"These securities are directly held by The Coloma 2021 Irrevocable Trust (the "Irrevocable Trust"), for which the reporting person and his spouse serve as co-trustees."

An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.

indirect financial

""direct_or_indirect": "I","nature_of_ownership": "The Coloma 2021 Irrevocable Trust""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/24/2026 - 04:15 PM Accepted by SEC EDGAR 06/24/2026 - 04:14 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coloma Jason V

(Last)

(First)

(Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/22/2026		S⁽¹⁾		1,953	D	$26.0015⁽²⁾	342,944	I	Coloma Family Trust⁽³⁾
Common Stock	06/22/2026		S⁽¹⁾		2,040	D	$26	25,930	I	The Coloma 2021 Irrevocable Trust⁽⁴⁾
Common Stock	06/23/2026		S⁽¹⁾		23,865	D	$26.0496⁽⁵⁾	319,079	I	Coloma Family Trust⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.025 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 5 of this Form 4.

3. These securities are directly held by the Coloma Family Trust (the "Family Trust"), for which the reporting person and his spouse serve as co-trustees.

4. These securities are directly held by The Coloma 2021 Irrevocable Trust (the "Irrevocable Trust"), for which the reporting person and his spouse serve as co-trustees.

5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.185 per share, inclusive.

	/s/ Courtney Phillips, as attorney-in-fact	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Maze Therapeutics (MAZE) disclose in this Form 4?

Maze Therapeutics disclosed that CEO and director Jason V. Coloma reported indirect open-market sales of 27,858 shares of common stock. The trades were executed through family-related trusts at weighted average prices near $26 per share, as detailed in the Form 4.

At what prices were the Maze Therapeutics (MAZE) shares sold in the reported transactions?

The reported weighted average prices were about $26 per share. Footnotes state trades occurred in ranges from $26.00 to $26.025 and from $26.00 to $26.185 per share, with exact breakdowns available on request from the issuer or the SEC staff.

Which entities actually held and sold the Maze Therapeutics (MAZE) shares?

The securities were held and sold by the Coloma Family Trust and The Coloma 2021 Irrevocable Trust. According to footnotes, Jason V. Coloma and his spouse serve as co-trustees of both trusts, and the holdings are reported as indirect ownership.

How many Maze Therapeutics (MAZE) shares did the insider sell in total in this filing?

The Form 4 shows net open-market sales of 27,858 shares of Maze Therapeutics common stock. This total reflects three separate non-derivative sale transactions reported across the family-related trusts, according to the transaction summary included in the filing.

Did the Maze Therapeutics (MAZE) Form 4 include any option exercises or derivative transactions?

No. The insider transactions reported are all non-derivative common stock sales coded as “S.” The derivativeSummary section is empty and the exerciseCount and exerciseShares fields in the transaction summary are zero, indicating no option or other derivative exercises in this filing.